vilastobart (XTX101)

DRUG2 trials

Sponsors

Xilio Development, Inc., Massachusetts General Hospital

Conditions

Advanced Solid TumorPancreatic Cancer Metastatic

Phase 1

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

CompletedNCT04896697

Xilio Development, Inc.Advanced Solid Tumor

Start: 2021-09-13End: 2026-05-18Updated: 2026-09-10

Phase 2

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

Not yet recruitingNCT07765836

Massachusetts General HospitalPancreatic Cancer Metastatic

Start: 2027-01-01End: 2030-12-31Target: 40Updated: 2026-08-14

Related Papers

Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti–CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC.

Journal of Clinical Oncology2025-05-281 citations

Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.

Journal of Clinical Oncology2025-01-271 citations

133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors

Immuno-Oncology Technology2023-12-01

Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-01

519 A first-in-human, multicenter, phase 1/2, open-label study of XTX101 in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-011 citations